Safety and Efficacy of Topical 0.1% And 0.05% Cyclosporine A in an Aqueous Solution in Steroid-Dependent Vernal Keratoconjunctivitis in a Population of Mexican Children
| Autor: | Ana C González-Villegas, Raul Suarez-Sanchez, Leopoldo Martín Baiza-Durán, Concepcion Santacruz-Valdes, Juan C Juarez-Echenique, Iris V Vizzuett-Lopez, Jose F Alaniz-de-la-O, Laura R. Saucedo-Rodríguez, Yussett Contreras-Rubio |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Chemosis
education.field_of_study medicine.medical_specialty business.industry medicine.medical_treatment Population medicine.disease Dermatology eye diseases Allergic conjunctivitis Tolerability Ophthalmology medicine Itching sense organs medicine.symptom education Adverse effect business Vernal keratoconjunctivitis Topical steroid |
| Zdroj: | Journal of Clinical & Experimental Ophthalmology. |
| ISSN: | 2155-9570 |
| Popis: | Purpose: Evaluate safety, efficacy and tolerability of 0.1% and 0.05% Cyclosporine A eye drops in Mexican children with Steroid Dependent Vernal Keratoconjunctivitis. Methods: This was a multicenter, prospective, randomized and double masked clinical trial where the effects of 0.1 and 0.05% cyclosporine A (aqueous solution) eyedrops were evaluated in children with steroid dependent Vernal Keratoconjunctivitis. Patient evaluation was done at baseline, 2, 7, 14, 30, 60, 90, 120, 150, and 180 days. Conjunctival discharge, conjunctival papillae size, conjunctival chemosis, tearing, itching, burning sensation, photophobia and conjunctival hyperemia were the primary endpoints. Results: 112 patients (224 eyes) with Vernal Keratoconjunctivitis were included (mean age=10.25 ± 3.83 years). 56 patients received 0.1% Cyclosporine eye drops, and another 56 patients got 0.05% Cyclosporine. Both treatments decreased the severity of all symptoms and clinical signs after 6 months (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|